RESprotect - Prevention of Chemoresistance

Chemogenomics

The chemogenomics approach of RESprotect has resulted in the identification of a validated target that contributes very strong to the development of chemoresistance by antagonizing apoptosis.

Combining our knowledge of genomic tools and our in-depth understanding of specific biological pathways qualifies us discover novel drug candidates that have the potential to affect the underlying disease rather than its symptoms.

Therapeutic approaches in cancer drug treatment rely on the induction of apoptosis of tumor cells, which is the main anticancer mechanism.
One major problem in chemotherapeutic treatment is the induction of chemoresistance, which antagonizes the apoptosis of cancer cells.
The chemogenomics approach of RESprotect has resulted in the identification of a number of validated targets that contribute to the development of chemoresistance by antagonizing apoptosis.

[ Back ]